Key facts
- It has raised $40.0M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Innoangel Fund, Lapam Capital, Shenzhen Yifeng Investment Management Enterprise, Tsinghua Holdings Capital, Ennovation Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for BDGENE
- ·The full record, as it builds
Funding rounds
No funding rounds for BDGENE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BDGENE
Developer of gene therapy drugs designed to cure eye diseases. The company offers gene editing, oncolytic virus platforms, lentiviral vectors, and gene delivery tools, enabling ophthalmologists to treat diabetic macular degeneration, age-related macular degeneration, and herpes simplex keratitis with improved precision and efficacy.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- bdgenetherapeutics.com/
- Ownership
- Privately Held (backing)
BDGENE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BDGENE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BDGENE in its N-PORT filings yet. We sweep new filings monthly.